Clofazimine
- Generic Name
- Clofazimine
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C27H22Cl2N4
- CAS Number
- 2030-63-9
- Unique Ingredient Identifier
- D959AE5USF
- Background
Clofazimine is a highly lipophilic antimicrobial riminophenazine dye used in combination with other agents, such as dapsone, for the treatment of leprosy. It was originally described in 1957 and was the prototypical riminophenazine dye - a bright-red dye that, in its clinical use, results in long-lasting discoloration of the skin and bodily fluids. Although ...
- Indication
Clofazimine is indicated for the treatment of lepromatous leprosy, including dapsone-resistant lepromatous leprosy and lepromatous leprosy complicated by erythema nodosum leprosum. To prevent the development of drug resistance, it should be used only in combination with other antimycobacterial leprosy treatments.
- Associated Conditions
- Lepromatous Leprosy
- Associated Therapies
- -
Patient-reported Experiences and Quality of Life Outcomes in the TB-PRACTECAL Clinical Trial
- First Posted Date
- 2019-05-08
- Last Posted Date
- 2024-05-29
- Lead Sponsor
- Medecins Sans Frontieres, Netherlands
- Target Recruit Count
- 137
- Registration Number
- NCT03942354
- Locations
- ๐ง๐พ
Republican Scientific and Practical Centre for Pulmonology and Tuberculosis hospital, Minsk, Belarus
๐บ๐ฟSh Alimov Republican Specialised Scientific-Practical Medical Centre for Phthysiology and Pulmonology Hospital, Tashkent, Uzbekistan
๐ฟ๐ฆHelen Jospeh Hospital, Johannesburg, South Africa
Efficacy and Tolerability of Bedaquiline, Delamanid, Levofloxacin, Linezolid, and Clofazimine to Treat MDR-TB
- Conditions
- Interventions
- First Posted Date
- 2019-02-04
- Last Posted Date
- 2024-04-12
- Lead Sponsor
- Boston University
- Target Recruit Count
- 220
- Registration Number
- NCT03828201
- Locations
- ๐ป๐ณ
National Lung Hospital, Hanoi, Vietnam
๐ต๐ญDe La Salle Health Sciences Institute, Dasmariรฑas, Philippines
Two-month Regimens Using Novel Combinations to Augment Treatment Effectiveness for Drug-sensitive Tuberculosis
- First Posted Date
- 2018-03-22
- Last Posted Date
- 2023-08-14
- Lead Sponsor
- University College, London
- Target Recruit Count
- 675
- Registration Number
- NCT03474198
- Locations
- ๐ฎ๐ฉ
Saiful Anwar Hospital, Malang, Indonesia
๐บ๐ฌJoint Clinical Research Centre, Mbarara, Uganda
๐บ๐ฌInfectious Diseases Institute, Kampala, Uganda
A Phase 2A Evaluation of the Safety, Tolerability, Pharmacokinetics, Efficacy of Clofazimine (CFZ) in Cryptosporidiosis
- First Posted Date
- 2017-11-14
- Last Posted Date
- 2019-08-13
- Lead Sponsor
- University of Washington
- Target Recruit Count
- 33
- Registration Number
- NCT03341767
- Locations
- ๐ฒ๐ผ
Malawi-Liverpool-Wellcome Trust Clinical Research Programme (MLW), Blantyre, Malawi
Clofazimine in the Treatment of Pulmonary Mycobacterium Avium Complex (MAC)
- Conditions
- Interventions
- First Posted Date
- 2016-11-18
- Last Posted Date
- 2024-12-19
- Lead Sponsor
- Oregon Health and Science University
- Target Recruit Count
- 102
- Registration Number
- NCT02968212
- Locations
- ๐บ๐ธ
National Jewish Health, Denver, Colorado, United States
๐บ๐ธUniversity of South Florida, Tampa, Florida, United States
๐บ๐ธUniversity of Chicago, Chicago, Illinois, United States
Evaluating Newly Approved Drugs for Multidrug-resistant TB
- First Posted Date
- 2016-04-28
- Last Posted Date
- 2024-07-24
- Lead Sponsor
- Mรฉdecins Sans Frontiรจres, France
- Target Recruit Count
- 754
- Registration Number
- NCT02754765
- Locations
- ๐ต๐ช
Hospital Nacional Dos de Mayo Parque Historia de la Medicina, Lima, Peru
๐ฐ๐ฟNational Center for Tuberculosis Problems, Almaty, Kazakhstan
๐ฌ๐ชNational Center for Tuberculosis and Lung Diseases, Tbilisi, Georgia
Pragmatic Clinical Trial for a More Effective Concise and Less Toxic MDR-TB Treatment Regimen(s)
- Conditions
- Interventions
- First Posted Date
- 2015-10-28
- Last Posted Date
- 2024-05-01
- Lead Sponsor
- Medecins Sans Frontieres, Netherlands
- Target Recruit Count
- 552
- Registration Number
- NCT02589782
- Locations
- ๐ฟ๐ฆ
King DinuZulu Hospital, Durban, KwaZulu-Natal, South Africa
๐บ๐ฟRepublican TB Hospital No. 2, Nukus, Karakalpakstan, Uzbekistan
๐ง๐พRepublican Scientific and Practical Centre for Pulmonology and Tuberculosis hospital, Minsk, Belarus
The Evaluation of a Standard Treatment Regimen of Anti-tuberculosis Drugs for Patients With MDR-TB
- First Posted Date
- 2015-04-06
- Last Posted Date
- 2023-09-28
- Lead Sponsor
- IUATLD, Inc
- Target Recruit Count
- 588
- Registration Number
- NCT02409290
- Locations
- ๐ช๐น
Armauer Hanssen Research Institute, Addis Ababa, Ethiopia
๐ช๐นSt. Peter's Tuberculosis Specializes Hospital, Addis Ababa, Ethiopia
๐ฌ๐ชJSC National Center for Tuberculosis and Lung Diseases, Tbilisi, Georgia
Effect of Additional Clofazimine on Erythema Nodosum Leprosum (ENL) Reactions in Leprosy
- Conditions
- Interventions
- First Posted Date
- 2011-02-07
- Last Posted Date
- 2015-06-04
- Lead Sponsor
- Paul Saunderson
- Target Recruit Count
- 100
- Registration Number
- NCT01290744
- Locations
- ๐ต๐ญ
Cebu Skin Clinic, Cebu, Vesayas, Philippines
Treatment Protocol for Clofazamine in the Long Term Treatment of Leprosy
- Conditions
- First Posted Date
- 2009-02-27
- Last Posted Date
- 2015-04-03
- Lead Sponsor
- Kaiser Permanente
- Registration Number
- NCT00852345
- Locations
- ๐บ๐ธ
Kaiser Permanente, Irvine, California, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.